Avid Bioservices Inc (CDMO)

[cjgaddy]

Dr. Bruce Freimark (Res.Dir./Preclin.Oncology) speaks today: GTC/I-O/SanDiego

Feb6-7 2017: “GTCbio’s 9th Immunotherapeutics & Immunomonitoring Conf.”, SanDiego
“Leading scientific & clinical experts from academia and industry will present the latest findings and developments in the exciting area of immunotherapeutics & immunomonitoring. New immunological concepts with clinically translational implications will be discussed, along with evaluations of novel drug targets & therapeutic approaches, the role of biomarkers in immunomonitoring, and the latest data on combinatorial treatments in the clinic.”
https://www.gtcbio.com/conferences/immunotherapeutics-immunomonitoring-overview
AGENDA: https://www.gtcbio.com/conferences/immunotherapeutics-immunomonitoring-agenda
2-7-17 TRACK: Combination Immunotherapy
2:05pm: “Tipping the Balance: Overriding Phosphatidylserine-mediated Tumor Immune Suppression to Enhance Immune Checkpoint Therapies”
Dr. Bruce Freimark (Res.Dir./Preclin.Oncology), Peregrine
Phosphatidylserine (PS) exposure in tumors induces non-inflammatory signals via multiple specific receptors for PS on tumors and immune cells, which contribute to immunosuppression in the tumor microenvironment. Antibody blockade of PS engages with innate immune responses and activates adaptive immune responses by promoting M1 macrophages, maturation of dendritic cells and tumor specific T-cell responses. Combinations of PS with CTLA-4, PD-1 and LAG-3 immune checkpoint antibodies have been shown to induce high levels of tumor regression and long-term anti-tumor immunity in models of breast and melanoma. These immune responses correlate with an overall increase in TILs, including CD8+ T cells with a reduction in suppressive Tregs and MDSCs, and tumor gene expression signatures indicating enhanced antigen presentation. Overall, PS blockade can complement immune checkpoint therapy by promoting a localized anti-tumor response and represents a promising strategy to enhance cancer immunotherapy.